Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0279765 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Rituvanthikaa Seethapathy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States of America. Hauptthemen laut MEDLINE: COVID-19, Renal Insufficiency. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences.
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) is an important risk factor for mortality from COVID-19. Remdesivir has been shown to shorten time to recovery in patients with severe COVID-19. However, exclusion of patients with severe kidney function impairment in clinical trials has led to concerns about kidney safety of remdesivir in patients with pre-existing kidney disease.
Methods
Retrospective propensity score matched cohort study of hospitalized patients with COVID-19 admitted with estimated glomerular filtration rate (eGFR) between 15 − 60 mL/min/1.73m 2 . Remdesivir-treated patients were 1:1 matched to historical comparators admitted during the first wave of COVID-19 (between March-April 2020) prior to emergency use authorization of remdesivir using propensity scores accounting for factors predicting treatment assignment. Dependent outcomes included in-hospital peak creatinine, incidence of doubling of creatine, rate of kidney replacement therapy initiation and eGFR among surviving patients at day 90.
Results
175 remdesivir-treated patients were 1:1 matched to untreated historical comparators. Mean age was 74.1 (SD 12.8), 56.9% were male, 59% patients were white, and the majority (83.1%) had at least one co-morbidity. There were no statistically significant differences in peak creatinine during hospitalization (2.3mg/dL vs. 2.5 mg/dL, P = 0.34), incidence of doubling of creatinine (10.3% vs. 13.1%, P = 0.48), and rate of kidney replacement therapy initiation (4.6% vs. 6.3%, P = 0.49) in remdesivir-treated patients versus matched untreated historical comparators, respectively. Among surviving patients, there was no difference of the average eGFR at day 90 (54.7 ± 20.0 mL/min/1.73m 2 for remdesivir-treated patients vs. 51.7 ± 19.5 mL/min/1.73m 2 for untreated comparators, P = 0.41).
Conclusions
Remdesivir use in patients with impaired kidney function (eGFR between 15 − 60 mL/min/1.73m 2 ) who present to the hospital with COVID-19 is not associated with increased risk of adverse kidney outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States of America.
- Department of Medicine, Mass General Brigham Salem Hospital, Salem, MA, United States of America.
ORCID-Profile: Rituvanthikaa Seethapathy
Förderung
- Gilead Sciences
Zitieren
APA
Seethapathy, R., Wang, Q., Zhao, S., Strohbehn, I. A., Long, J. D., Dinulos, J. E., Harden, D., Kadiyala, V. B., Moreno, D., & Sise, M. E. (2023). Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function. PLOS ONE. https://doi.org/10.1371/journal.pone.0279765
Vancouver
Seethapathy R, Wang Q, Zhao S, Strohbehn IA, Long JD, Dinulos JE, et al. Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function. PLOS ONE. 2023. doi:10.1371/journal.pone.0279765
BibTeX
@article{Seethapathy2023,
author = {Seethapathy, Rituvanthikaa and Wang, Qiyu and Zhao, Sophia and Strohbehn, Ian A and Long, Joshua D and Dinulos, James E and Harden, Destiny and Kadiyala, Vinay B and Moreno, Daiana and Sise, Meghan E},
title = {Effect of remdesivir on adverse kidney outcomes in hospitalized patients with COVID-19 and impaired kidney function},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0279765}
}
EUVIMED